Tumor penetrability and anti-angiogenesis using iRGD-mediated delivery of doxorubicin-polymer conjugates

Biomaterials

Volumn 35, Issue 30, 2014, Pages 8735-8747

  Wang, Ke ^a   Zhang, Xiaofeng ^a   Liu, Yang ^b,c   Liu, Chang ^a   Jiang, Baohong ^b   Jiang, Yanyan ^a  

^a FUDAN UNIVERSITY   (China)

^b SHANGHAI INSTITUTE OF MATERIA MEDICA   (China)

^c SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Co administration; Conjugates; IRGD; Tumor vascular permeability; Tumor penetrating peptide

Indexed keywords

BLOOD VESSELS; CELL CULTURE; DRUG DELIVERY; GLYCOPROTEINS; PEPTIDES;

CO-ADMINISTRATION; CONJUGATES; IRGD; TUMOR-PENETRATING PEPTIDES; VASCULAR PERMEABILITY;

TUMORS;

ARGINYLGLYCYLASPARTIC ACID; DOXORUBICIN; DRUG CARRIER; INTERNALIZING ARGINYLGLYCYLASPARTIC ACID; UNCLASSIFIED DRUG; ANGIOGENESIS INHIBITOR; ARGINYL-GLYCYL-ASPARTIC ACID; CELL PENETRATING PEPTIDE; DENDRIMER; MACROGOL DERIVATIVE; OLIGOPEPTIDE; PEG-PAMAM; POLYMER;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD VESSEL DIAMETER; BRAIN TUMOR; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG PENETRATION; DRUG TUMOR PENETRATION; GLIOMA; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PERMEABILITY; PRIORITY JOURNAL; TUMOR SPHEROID; VASCULAR TUMOR; ANIMAL; AREA UNDER THE CURVE; CAPILLARY PERMEABILITY; CHEMISTRY; DRUG DELIVERY SYSTEM; DRUG EFFECTS; ENDOCYTOSIS; HUMAN; IC50; INSTITUTE FOR CANCER RESEARCH MOUSE; KAPLAN MEIER METHOD; MALE; NEOPLASMS; PATHOLOGY; TISSUE DISTRIBUTION; TREATMENT OUTCOME; TUMOR CELL LINE; VASCULARIZATION;

ANGIOGENESIS INHIBITORS; ANIMALS; AREA UNDER CURVE; CAPILLARY PERMEABILITY; CELL LINE, TUMOR; CELL-PENETRATING PEPTIDES; DENDRIMERS; DOXORUBICIN; DRUG DELIVERY SYSTEMS; ENDOCYTOSIS; HUMANS; INHIBITORY CONCENTRATION 50; KAPLAN-MEIER ESTIMATE; MALE; MICE, INBRED ICR; NEOPLASMS; OLIGOPEPTIDES; POLYETHYLENE GLYCOLS; POLYMERS; TISSUE DISTRIBUTION; TREATMENT OUTCOME;

EID: 84904727941     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2014.06.042     Document Type: Article

References (33)

1. Siegel R., Naishadham D., Jemal A. Cancer statistics. CA Cancer J Clin 2012, 62:10-29.
2. Agarwal S., Sane R., Oberoi R., Ohlfest J.R., Elmquist W.F. Delivery of molecularly targeted therapy to malignant glioma, a disease of the whole brain. Expert Rev Mol Med 2011, 13:e17.
3. Newton H.B. Advances in strategies to improve drug delivery to brain tumors. Expert Rev Neurother 2006, 6:1495-1509.
4. Silvani A., Gaviani P., Lamperti E., Botturi A., Ferrari D., Simonetti G., et al. Malignant gliomas: early diagnosis and clinical aspects. Neurol Sci 2011, 322:S207-S208.
5. Hilgenbrink A.R., Low P.S. Folate receptor-mediated drug targeting: from therapeutics to diagnostics. J Pharm Sci 2005, 94:2135-2146.
6. Xu L.A., Pirollo K.F., Tang W.H., Rait A., Chang E.H. Transferrin-liposome-mediated systemic p53 gene therapy in combination with radiation results in regression of human head and neck cancer xenografts. Hum Gene Ther 1999, 10:2941-2952.
7. Zhang Y., Wang J., Bian D., Zhang X., Zhang Q. Targeted delivery of RGD-modified liposomes encapsulating both combretastatin A-4 and doxorubicin for tumor therapy: in vitro and in vivo studies. Eur J Pharm Biopharm 2010, 74:467-473.
8. Zhu S., Qian L., Hong M., Zhang L., Pei Y., Jiang Y. RGD-modified PEG-PAMAM-DOX conjugate: in vitro and in vivo targeting to both tumor neovascular endothelial cells and tumor cells. Adv Mater 2011, 23:H84-H89.
9. Zhang L., Zhu S., Qian L., Pei Y., Qiu Y., Jiang Y. RGD-modified PEG-PAMAM-DOX conjugates: in vitro and in vivo studies for glioma. Eur J Pharm Biopharm 2011, 79:232-240.
10. Zhang F., Huang X., Zhu L., Guo N., Niu G., Swierczewska M., et al. Noninvasive monitoring of orthotopic glioblastoma therapy response using RGD-conjugated iron oxide nanoparticles. Biomaterials 2012, 33:5414-5422.
11. Cai W., Chen K., Li Z., Gambhir S.S., Chen X. Dual-function probe for PET and near-infrared fluorescence imaging of tumor vasculature. J Nucl Med 2007, 48:1862-1870.
12. Sugahara K.N., Teesalu T., Karmali P.P., Kotamraju V.R., Agemy L., Girard O.M., et al. Tissue-penetrating delivery of compounds and nanoparticles into tumors. Cancer Cell 2009, 16:510-520.
13. Sugahara K.N., Teesalu T., Karmali P.P., Kotamraju V.R., Agemy L., Greenwald D.R., et al. Coadministration of a tumor-penetrating peptide enhances the efficacy of cancer drugs. Science 2010, 328:1031-1035.
14. Wang X., Zhen X., Wang J., Zhang J., Wu W., Jiang X. Doxorubicin delivery to 3D multicellular spheroids and tumors based on boronic acid-rich chitosan nanoparticles. Biomaterials 2013, 34:4667-4679.
15. Yu K.F., Zhang W.Q., Luo L.M., Song P., Li D., Du R., et al. The antitumor activity of a doxorubicin loaded, iRGD-modified sterically-stabilized liposome on B16-F10 melanoma cells: in vitro and in vivo evaluation. Int J Nanomedicine 2013, 8:2473-2485.
16. Zhang H.T., Li H.C., Li Z.W., Guo C.H. A tumor-penetrating peptide modification enhances the antitumor activity of endostatin in vivo. Anticancer Drugs 2011, 22:409-415.
17. Gu G.Z., Gao X.L., Hu Q.Y., Kang T., Liu Z.Y., Jiang M.Y., et al. The influence of the penetrating peptide iRGD on the effect of paclitaxel-loaded MT1-AF7p-conjugated nanoparticles on glioma cells. Biomaterials 2013, 34:5138-5148.
18. Song W.T., Li M.Q., Tang Z.H., Li Q.S., Yang Y., Liu H.Y., et al. Methoxypoly(ethylene glycol)-block-poly(l-glutamic acid)-loaded cisplatin and a combination with iRGD for the treatment of non-small-cell lung cancers. Macromol Biosci 2012, 12:1514-1523.
19. Ruoslahti E. Peptides as targeting elements and tissue penetration devices for nanoparticles. Adv Mater 2012, 24:3747-3756.
20. Zhu S., Hong M., Tang G., Qian L., Lin J., Jiang Y., et al. Partly PEGylated polyamidoamine dendrimer for tumor-selective targeting of doxorubicin: the effects of PEGylation degree and drug conjugation style. Biomaterials 2010, 31:1360-1371.
21. Heldin C.H., Rubin K., Pietras K., Ostman A. High interstitial fluid pressure-an obstacle in cancer therapy. Nat Rev Cancer 2004, 4:806-813.
22. Liu Y., Ji M., Wong M.K., Joo K., Wang P. Enhanced therapeutic efficacy of iRGD-conjugated crosslinked multilayer liposomes for drug delivery. Biomed Res Int 2013, 2013:378-380.
23. Akashi Y., Oda T., Ohara Y., Miyamoto R., Kurokawa T., Hashimoto S., et al. Anticancer effects of gemcitabine are enhanced by co-administered iRGD peptide in murine pancreatic cancer models that overexpressed neuropilin-1. Br J Cancer 2014, 110:1481-1487.
24. Yu M., Karmakar S., Yang J., Zhang H., Yang Y., Thorn P., et al. Facile synthesis of ultra-small hybrid silica spheres for enhanced penetration in 3D glioma spheroids. Chem Commun (Camb) 2014, 50:1527-1529.
25. McMahon K.M., Volpato M., Chi H.Y., Musiwaro P., Poterlowicz K., Peng Y., et al. Characterization of changes in the proteome in different regions of 3D multicell tumor spheroids. J Proteome Res 2012, 11:2863-2875.
26. Chen Z.Y., Deng J.X., Zhao Y., Tao T. Cyclic RGD peptide-modified liposomal drug delivery system: enhanced cellular uptake in vitro and improved pharmacokinetics in rats. Int J Nanomedicine 2012, 7:3803-3811.
27. Naik S., Patel D., Chuttani K., Mishra A.K., Misra A. In vitro mechanistic study of cell death and in vivo performance evaluation of RGD grafted PEGylated docetaxel liposomes in breast cancer. Nanomedicine 2012, 8:951-962.
28. Chauhan V.P., Stylianopoulos T., Martin J.D., Popovic Z., Chen O., Kamoun W.S., et al. Normalization of tumour blood vessels improves the delivery of nanomedicines in a size-dependent manner. Nat Nanotechnol 2012, 7:383-388.
29. Hatakeyama H., Ishida E., Kobayashi H., Yasuda J., Kikuchi H., Kiwada H. Tumor targeting of doxorubicin by anti-MT1-MMP antibody-modified PEG liposomes. Int J Pharm 2007, 342:194-200.
30. Tong R.T., Boucher Y., Kozin S.V., Winkler F., Hicklin D.J., Jain R.K. Vascular normalization by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors. Cancer Res 2004, 64:3731-3736.
31. Baker J.H., Lam J., Kyle A.H., Sy J., Oliver T., Co S.J., et al. A novel nanoformulation of irinotecan, alters tumor vascular function and enhances the distribution of 5-fluorouracil and doxorubicin. Clin Cancer Res 2008, 14:7260-7271.
32. Escorcia F.E., Henke E., McDevitt M.R., Villa C.H., Smith-Jones P., Blasberg R.G., et al. Selective killing of tumor neovasculature paradoxically improves chemotherapy delivery to tumors. Cancer Res 2010, 70:9277-9286.
33. Verreault M., Strutt D., Masin D., Anantha M., Yung A., Kozlowski P., et al. Vascular normalization in orthotopic glioblastoma following intravenous treatment with lipid-based nanoparticulate formulations of irinotecan (Irinophore C (TM)), doxorubicin (Caelyx (R)) or vincristine. BMC Cancer 2011, 11:e124.